Ginkgo Bioworks Holdings, Inc. is a synthetic-biology company whose "foundry" platform programs cells for industries such as pharmaceuticals, agriculture, and industrial materials. It is a stock, not an exchange-traded fund, and it is best understood through its own fundamentals and a very thin, cautious sell-side view.
Reliable, current analyst coverage is limited, and — importantly — the published targets sit below the latest market price. Recent verified targets include BTIG's $5 (Sell, reiterated September 2026) and TD Cowen's $11 (Hold, raised from $9 on October 13, 2026); William Blair also maintains a Sell without a public price target. Aggregators that poll three analysts show a range of about $5 to $11 and an average near $8, implying downside rather than upside from the stock's recent $11.21 level.
Because no credible analyst target currently sits meaningfully above the market price, the $18 figure in this analysis is a fallback objective drawn from public market structure rather than an analyst consensus. It is anchored to DNA's 52-week high of $18.22, a level the stock briefly reached on October 6, 2026, during a sharp, high-volume surge. In short, $18 represents a retest of a recently established high — not a forecast, and not an official published consensus.
DNA last traded around $11.21, well off its $5.37 52-week low but also roughly 38% below its $18.22 peak. Reaching $18 would require an additional advance of about 60% from current levels — a very large move by any conventional measure, even for a stock that has already demonstrated extreme volatility this year.
The path toward $18 would depend less on a steady earnings ramp and more on a resumption of the momentum and sentiment shift seen in early October. Ginkgo is not yet profitable: it reported an EPS (earnings per share) of negative $0.75 for the second quarter of 2026, beating estimates, while revenue of about $20.2 million came in below expectations. Full-year 2026 revenue is projected to decline sharply, and the company's cash position of roughly $474 million with no bank debt gives it runway but does not by itself create growth.
Several factors could, in theory, re-ignite buying interest. TD Cowen's October target increase cited what the firm called one of the strongest quarters in 20 years for the life-sciences-tools sector, driven by biotech funding, AI-related demand, and improving commercial execution. Ginkgo's aggressive cost cutting and strategic refocus have narrowed losses, and its cash-rich, debt-light balance sheet reduces near-term solvency risk. Any upside surprise in upcoming earnings, new partnership announcements, or renewed investor appetite for AI-adjacent synthetic-biology themes could support a recovery toward prior highs.
The obstacles are substantial. Revenue is contracting — expectations point to a decline of roughly half in 2026 — and the company remains deeply unprofitable on both an EPS and EBITDA (earnings before interest, taxes, depreciation, and amortization) basis. Analysts have repeatedly flagged limited visibility on near-term growth and revenue recognition, which drove TD Cowen's earlier downgrade to Hold from Buy. With a consensus rating near "Sell" and every published target at or below the current price, the stock lacks fundamental support from the sell-side. The extreme volatility itself — including a drop from an intraday high of $18.22 in early October to the low-$11 range weeks later — underscores how quickly momentum can reverse.
DNA's recent price action defines the relevant map. The $18.22 print from October 6, 2026, marks the clear resistance level the central target represents. Below it, the stock has consolidated in a wide band, with the $10-to-$11 area acting as a near-term support level and the $5.37 52-week low representing deeper support. A sustained close back above the mid-teens would be a prerequisite for any credible challenge of the $18 zone, while failure to hold the low teens could reopen the path toward the single digits.
Because the $18 target is a technical milestone rather than a formal analyst price target, it carries no defined research horizon. The most relevant upcoming catalyst is Ginkgo's third-quarter earnings report, scheduled for November 5, 2026. Investors should watch revenue versus expectations, any updated full-year guidance, commentary on cost reductions and cash burn, new platform or partnership developments, and any further analyst target or rating changes. Broader biotech funding conditions and sentiment toward AI-linked life-sciences themes will also matter, given how quickly this stock has repriced.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name such as DNA, these signals can help traders spot emerging momentum shifts, monitor existing positions, and scan for new opportunities more efficiently than manual chart review. Explore the AI Daily Buy/Sell Signals to see how AI-driven monitoring fits into your routine.
The question of whether Ginkgo Bioworks stock can reach $18 is really a question about whether the market's early-October optimism can return. The $18 objective is a technical milestone tied to the 52-week high, not a published analyst forecast — and that distinction matters, because the actual analyst view is cautious, with targets of roughly $5 to $11 and an average near $8 that sits below the current price. Reaching $18 would demand a move of about 60%, which is very large and would require renewed momentum, improving revenue visibility, and sustained sector enthusiasm. The company's cash position and cost discipline provide a foundation, but falling sales, ongoing losses, and limited near-term visibility are meaningful obstacles. Investors should monitor the November earnings report and any analyst revisions as the next checkpoints, without treating the $18 level as a prediction or a recommendation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, DNA has been loosely correlated with TWST. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To DNA | 1D Price Change % | ||
|---|---|---|---|---|
| DNA | 100% | -14.65% | ||
| TWST - DNA | 63% Loosely correlated | -7.22% | ||
| RXRX - DNA | 61% Loosely correlated | +1.13% | ||
| VCYT - DNA | 58% Loosely correlated | +4.36% | ||
| ABSI - DNA | 53% Loosely correlated | +1.50% | ||
| NTLA - DNA | 53% Loosely correlated | +2.15% | ||
More | ||||